Literature DB >> 11553879

Osteoblast cell death on methacrylate polymers involves apoptosis.

J E Gough1, S Downes.   

Abstract

The success of an implant depends on the implant-tissue interface. There are many causes of implant failure, one of which is tissue necrosis. The aim of this in vitro study was to determine whether cell death of primary human osteoblasts (implant site specific cells) occurred by apoptosis (a form of programmed cell death) on two methacrylate polymers. Cells were cultured on poly(ethyl methacrylate)/tetrahydrofurfuryl methacrylate and poly(methyl methacrylate in the form of 13-mm discs, in conditioned medium containing leachable monomer and in the presence of various concentrations of monomer itself in the culture medium. It was found that monomer and leached monomer caused apoptosis of human osteoblast cells in this system. Tetrahydrofurfuryl methacrylate monomer was found to be more toxic than currently used monomer methylmethacrylate. Preincubation of polymers in serum containing medium was found to increase the biocompatibility of the polymers. High levels of apoptosis occurred on polymer used directly after polymerization. Apoptosis levels were decreased after polymer was incubated at 60 degrees C overnight or for 3 days. Apoptosis therefore may occur in cells at the implant site in vivo. Copyright 2001 John Wiley & Sons, Inc. J Biomed Mater Res 57: 497-505, 2001

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553879     DOI: 10.1002/1097-4636(20011215)57:4<497::aid-jbm1195>3.0.co;2-u

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  9 in total

1.  Functional evaluation and testing of a newly developed Teleost's Fish Otolith derived biocomposite coating for healthcare.

Authors:  Nerly D Montañez; Heider Carreño; Patricia Escobar; Hugo A Estupiñán; Darío Y Peña; Saurav Goel; Jose L Endrino
Journal:  Sci Rep       Date:  2020-01-14       Impact factor: 4.379

2.  Treatment of MM-associated spinal fracture with percutaneous vertebroplasty (PVP) and chemotherapy.

Authors:  Zuozhang Yang; Jing Tan; Yongqing Xu; Hongpu Sun; Lin Xie; Ruilian Zhao; Jiaping Wang; Hua Jiang
Journal:  Eur Spine J       Date:  2011-12-16       Impact factor: 3.134

3.  Trabecular resorption patterns of cement-bone interlock regions in total knee replacements.

Authors:  Jacklyn R Goodheart; Mark A Miller; Megan E Oest; Kenneth A Mann
Journal:  J Orthop Res       Date:  2017-05-15       Impact factor: 3.494

4.  Fluid-structure interactions in micro-interlocked regions of the cement-bone interface.

Authors:  Kenneth A Mann; Mark A Miller
Journal:  Comput Methods Biomech Biomed Engin       Date:  2013-03-12       Impact factor: 1.763

5.  Changes in microgaps, micromotion, and trabecular strain from interlocked cement-trabecular bone interfaces in total knee replacements with in vivo service.

Authors:  Mark A Miller; Jacklyn R Goodheart; Benjamin Khechen; Dennis Janssen; Kenneth A Mann
Journal:  J Orthop Res       Date:  2015-12-10       Impact factor: 3.494

6.  [Use of the injectable bone cement Norian SRS for tibial plateau fractures. Results of a prospective 30-month follow-up study].

Authors:  A Jubel; J Andermahr; J Mairhofer; A Prokop; U Hahn; K E Rehm
Journal:  Orthopade       Date:  2004-08       Impact factor: 1.087

Review 7.  Cytocompatibility of medical biomaterials containing nickel by osteoblasts: a systematic literature review.

Authors:  Marcin Mikulewicz; Katarzyna Chojnacka
Journal:  Biol Trace Elem Res       Date:  2010-08-12       Impact factor: 3.738

Review 8.  Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review.

Authors:  Sunjeev S Phull; Alireza Rahimnejad Yazdi; Michelle Ghert; Mark R Towler
Journal:  J Bone Oncol       Date:  2020-12-16       Impact factor: 4.072

9.  Embryotoxic and teratogenic effects of nickel in Swiss albino mice during organogenetic period.

Authors:  Shivi Saini; Neena Nair; Mali Ram Saini
Journal:  Biomed Res Int       Date:  2013-07-15       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.